Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed
Entrada Therapeutics Employees
Entrada Therapeutics had 159 employees as of December 31, 2023. The number of employees increased by 29 or 22.31% compared to the previous year.
Employees
159
Change (1Y)
29
Growth (1Y)
22.31%
Revenue / Employee
$1,353,660
Profits / Employee
$345,604
Market Cap
655.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Dec 31, 2021 | 114 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CureVac | 1,172 |
| Revance Therapeutics | 597 |
| Exscientia | 483 |
| Axogen | 428 |
| Allogene Therapeutics | 233 |
| IRADIMED CORPORATION | 148 |
| Alumis | 109 |
| Tectonic Therapeutic | 44 |
TRDA News
- 27 days ago - Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire
- 6 weeks ago - Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - GlobeNewsWire
- 7 weeks ago - āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Business Wire
- 2 months ago - Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - GlobeNewsWire
- 4 months ago - Entrada Therapeutics Announces $100 Million Registered Direct Offering - GlobeNewsWire
- 4 months ago - Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy - GlobeNewsWire
- 5 months ago - Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire